Weight loss · Phoenix area, AZ
Weight loss and obesity studies in Phoenix area, AZ
28 recruiting studies have a site in the Phoenix area. This page includes nearby cities such as Scottsdale, Tempe, Mesa, Chandler.
28 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersPhase 3
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Location
- Chandler, AZ + 55 other US sites
- Eligibility basics
- Ages 18–79
- RecruitingPhase 3
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Amgen
- Location
- Chandler, AZ + 51 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 2
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
AbbVie
- Location
- Scottsdale, AZ + 58 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
Alveus Therapeutics, Inc.
- Location
- Sun City, AZ + 19 other US sites
- Eligibility basics
- Ages 18–75
- Recruiting
The RESET System Pivotal Clinical Trial (Protocol Revision K)
Morphic Medical Inc.
- Location
- Gilbert, AZ + 25 other US sites
- Eligibility basics
- Ages 22–65
- RecruitingPhase 3
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
AstraZeneca
- Location
- Chandler, AZ + 43 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
Eli Lilly and Company
- Location
- Phoenix, AZ + 24 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Amgen
- Location
- Phoenix, AZ + 136 other US sites
- Eligibility basics
- Ages 45–99
- RecruitingPhase 3
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
Eli Lilly and Company
- Location
- Mesa, AZ + 37 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
Eli Lilly and Company
- Location
- Chandler, AZ + 39 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Eli Lilly and Company
- Location
- Mesa, AZ + 68 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Eli Lilly and Company
- Location
- Chandler, AZ + 42 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
Novo Nordisk A/S
- Location
- Gilbert, AZ + 18 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
Amgen
- Location
- Gilbert, AZ + 30 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
Eli Lilly and Company
- Location
- Scottsdale, AZ + 40 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
Eli Lilly and Company
- Location
- Phoenix, AZ + 55 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Amgen
- Location
- Phoenix, AZ + 117 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 3
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Ascletis Pharma (China) Co., Limited
- Location
- Phoenix, AZ + 5 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Ascletis Pharma (China) Co., Limited
- Location
- Phoenix, AZ + 5 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 4
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice…
Eli Lilly and Company
- Location
- Phoenix, AZ + 38 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
Novo Nordisk A/S
- Location
- Gilbert, AZ + 129 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1
Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants
Terrestrial Bio, Inc.
- Location
- Tempe, AZ
- Eligibility basics
- Ages 18–60
- RecruitingPhase 3
A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
Novo Nordisk A/S
- Location
- Phoenix, AZ + 18 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1/Phase 2
A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)
Regeneron Pharmaceuticals
- Location
- Chandler, AZ + 1 other US site
- Eligibility basics
- Ages 18–65
Who these studies look for
Most of these studies set a BMI range and may exclude people taking certain weight-loss medicines or who have had bariatric surgery. Some require a weight-related condition such as type 2 diabetes or high blood pressure.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.